The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma

被引:3
|
作者
Xiang, Xiaoyong [1 ,2 ]
Chen, Peng [1 ,2 ]
Lan, Fengming [1 ,2 ]
Ma, Li [1 ,2 ]
Jin, Jing [1 ,2 ,3 ]
Zhang, Ye [3 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp & Shenzhen Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Shenzhen, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
nasopharyngeal carcinoma; locoregionally advanced; induction chemotherapy; short-term efficacy; PD-1; GROWTH-FACTOR RECEPTOR; CHEMORADIOTHERAPY; MULTICENTER; RADIOTHERAPY; GEMCITABINE; EXPRESSION; PLACEBO; PHASE-3; NPC;
D O I
10.3389/fonc.2023.1110281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThis study aimed to investigate the short-term efficacy and safety of induction chemotherapy (IC) combined with PD-1 inhibitor or anti-EGFR in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Methods and materialsWe retrospectively reviewed the clinical data of 206 patients with LA-NPC, including IC combined with anti-PD-1 (57 patients), IC combined with anti-EGFR (28 patients), and IC alone (121 patients). The short-term efficacy was assessed at the end of IC and one month after overall treatment. According to the RECIST v1.1, the short-term efficacy of cervical lymph nodes and primary nasopharynx foci was divided into complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). The overall response (ORR) was defined as the sum of CR and PR. Acute toxicities were graded according to the CTCAE v5.0. One-way analysis of variance (ANOVA) was used to compare differences in the numerical variables among groups. Fisher Freeman-Halton test or Pearson Chi-square test was used to compare classified variables. ResultsThe ORR rates of primary nasopharynx foci in IC, anti-EGFR, and anti-PD-1 group were 68.60%, 67.9%, and 94.7%, respectively, and the corresponding rates of ORR in cervical lymph nodes were 78.5%, 71.4%, and 93.0%, respectively. There was a statistical difference in the ORR between the three groups. Further analysis showed that after IC or overall treatment, the CR rate of primary nasopharynx foci in the anti-PD-1 group was significantly higher than the other two groups. The most common adverse effects were hematotoxicity, gastrointestinal toxicity, and transaminase elevation. However, there were no statistical differences in the frequency of any common adverse effects between the three groups. ConclusionsThe addition of anti-PD-1 based on IC significantly improved the short-term efficacy of LA-NPC and toxicities were tolerable.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The Short-Term Efficacy and Safety of Induction Chemotherapy Combined with PD-1 Inhibitor or Anti-EGFR in Locoregionally Advanced Nasopharyngeal Carcinoma
    Xiang, X.
    Chen, P.
    Lan, F.
    Ma, L.
    Jin, J.
    Zhang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E635 - E635
  • [2] Efficacy and Safety of Combined PD-1 Inhibitor With Induction Chemotherapy Followed by IMRT Plus Nimotuzumab in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Analysis
    Chen, Kebin
    Huang, Xiaopeng
    Chen, Jiawei
    Zhang, Shuai
    ONCOTARGETS AND THERAPY, 2025, 18 : 283 - 296
  • [3] Efficacy and safety of PD-1 inhibitor plus chemotherapy in advanced nasopharyngeal carcinoma: A meta-analysis
    Yan, Xin
    Chen, Suhua
    Dai, Guoping
    Liu, Yingxin
    TUMORI JOURNAL, 2025, 111 (01): : 88 - 99
  • [4] Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma
    Yu, Yi-Feng
    Lu, Guan-Zhong
    Wang, Run-Jie
    Song, Yu-Kun
    Wu, San-Gang
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [5] Efficacy and safety of PD-1 inhibitor combined with anlotinib in the treatment of advanced
    Song, L.
    Yu, X.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 145 - 145
  • [6] MRI-based deep learning and radiomics for predicting the efficacy of PD-1 inhibitor combined with induction chemotherapy in advanced nasopharyngeal carcinoma: A prospective cohort study
    Wang, Yiru
    Chen, Fuli
    Ouyang, Zhechen
    He, Siyi
    Qin, Xinling
    Liang, Xian
    Huang, Weimei
    Wang, Rensheng
    Hu, Kai
    TRANSLATIONAL ONCOLOGY, 2025, 52
  • [7] The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis
    Jin, Ya-Nan
    Qiang, Meng-Yun
    Wang, Ying
    Lin, Yu-Jing
    Jiang, Ren-Wei
    Cao, Wan-Wei
    Zhang, Wang-Jian
    Wang, Si-Yang
    Zhang, Hong-Yu
    Yao, Ji-Jin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (07)
  • [8] Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort
    Yao, Yangyang
    Ouyang, Qingqing
    Wang, Songlin
    Li, Ke
    Luo, Qing
    Qiu, Lingping
    Liu, Fenfen
    Tan, Lei
    Li, Qingqing
    Ren, Biao
    Long, Ping
    Ye, Jing
    Zhong, Xiaojun
    ORAL ONCOLOGY, 2024, 154
  • [9] A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
    Lei, Yuan
    Li, Ying-Qin
    Jiang, Wei
    Hong, Xiao-Hong
    Ge, Wen-Xiu
    Zhang, Yuan
    Hu, Wei-Han
    Wang, Ya-Qin
    Liang, Ye-Lin
    Li, Jun-Yan
    Cho, William C. S.
    Yun, Jing-Ping
    Zeng, Jing
    Chen, Jie-Wei
    Liu, Li-Zhi
    Li, Li
    Chen, Lei
    Xie, Fang-Yun
    Li, Wen-Fei
    Mao, Yan-Ping
    Liu, Xu
    Chen, Yu-Pei
    Tang, Ling-Long
    Sun, Ying
    Liu, Na
    Ma, Jun
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (04): : 471 - 480
  • [10] The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma
    Shen, Dijian
    Chen, Qixun
    Wu, Jie
    Li, Jianqiang
    Tao, Kaiyi
    Jiang, Youhua
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (01) : 1 - 10